TIL therapy for advanced uveal melanoma and sarcomas
Treatments studied
Part of Cancer, Eyes & vision, Skin clinical trials.
This trial tests using your own immune cells (TILs) to fight advanced uveal melanoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, or angiosarcoma. It aims to see if this treatment can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these cancers that has spread or cannot be removed surgically.
- You need at least one tumor that is 1.5 cm or larger and can be removed for the TIL manufacturing.
- You must have recovered from any side effects of prior cancer treatments before starting the study.
- You must be 18 or older and in reasonably good health, with a life expectancy of at least 6 months.
- Blood and organ function tests must meet certain thresholds (your doctor will check these).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a treatment using a patient’s own immune cells (TILs) plus a brief period of chemotherapy to help the immune system fight melanoma that has spread mainly to the liver. It may be an option if your melanoma has progressed after prior medicines and you have liver lesions that can be removed to make the cells.
This trial tests a personalized cell therapy using your own immune cells (TILs) grown in a lab. It is for people with advanced melanoma that did not respond to or stopped responding to prior immunotherapy.
This trial tests if immune cells taken from a liver tumor can be given back to fight metastatic melanoma. It is for people with stage IV uveal or cutaneous melanoma that has worsened after standard treatments.
This trial tests a new way to treat advanced melanoma by taking immune cells from your tumor, enhancing them in the lab to fight better, and giving them back to you. It is for people whose melanoma has spread or cannot be removed, and who have already tried standard treatments.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a new T-cell therapy made from your own tumor (TILs), genetically edited to remove the PD1 checkpoint blocker. It may help your immune system fight melanoma that has not responded to standard treatments like anti-PD1 therapy.
Hear when a new Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.